TGF-β signaling pathway as a pharmacological target in liver diseases

被引：33
作者：
Zhang, Sen [1 ]
Sun, Wu-Yi [1 ]
Wu, Jing-Jing [1 ]
Wei, Wei [1 ]
机构：
[1] Anhui Med Univ, Inst Clin Pharmacol, Key Lab Antiinflammatory & Immune Med, Minist Educ, Hefei 230032, Anhui, Peoples R China
来源：
PHARMACOLOGICAL RESEARCH | 2014年 / 85卷
基金：
高等学校博士学科点专项科研基金;
关键词：
Transforming growth factor beta; Signaling pathway; Liver diseases; Pharmacological target; Targeted drugs; GROWTH-FACTOR-BETA; RECEPTOR KINASE DOMAIN; HEPATOCELLULAR-CARCINOMA; MESENCHYMAL TRANSITION; CROSS-TALK; ACTIVIN-A; INHIBITOR; CANCER; FIBROGENESIS; PROGRESSION;
D O I：
10.1016/j.phrs.2014.05.005
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Transforming growth factor beta (TGF-beta) belongs to a class of pleiotropic cytokines that are involved in the processes of embryonic development, wound healing, cell proliferation, and differentiation. Moreover, TGF-beta is also regarded as a central regulator in the pathogenesis and development of various liver diseases because it contributes to almost all of the stages of disease progression. A range of liver cells are considered to secrete TGF-beta ligands and express related receptors and, consequently, play a crucial role in the progression of liver disease via different signal pathways. In this manuscript, we review the role of the TGF-beta signaling pathway in liver disease and the potential of targeting the TGF-beta signaling in the pharmacological treatment of liver diseases. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码：15 / 22
页数：8
相关论文
共 57 条
  • [1] Targeting the TGFβ signalling pathway in disease
    Akhurst, Rosemary J.
    Hata, Akiko
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (10) : 790 - 811
  • [2] Extracellular domain of TGFβ type III receptor inhibits angiogenesis and tumor growth in human cancer cells
    Bandyopadhyay, A
    Zhu, Y
    Malik, SN
    Kreisberg, J
    Brattain, MG
    Sprague, EA
    Luo, J
    López-Casillas, F
    Sun, LZ
    [J]. ONCOGENE, 2002, 21 (22) : 3541 - 3551
  • [3] TGF-β signaling in fibrosis
    Biernacka, Anna
    Dobaczewski, Marcin
    Frangogiannis, Nikolaos G.
    [J]. GROWTH FACTORS, 2011, 29 (05) : 196 - 202
  • [4] Role of cytokines and chemokines in non-alcoholic fatty liver disease
    Braunersreuther, Vincent
    Viviani, Giorgio Luciano
    Mach, Francois
    Montecucco, Fabrizio
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (08) : 727 - 735
  • [5] Alcoholic liver disease
    Bruha, Radan
    Dvorak, Karel
    Petrtyl, Jaromir
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2012, 4 (03) : 81 - 90
  • [6] Epithelial-to-Mesenchymal Transitions in the Liver
    Choi, Steve S.
    Diehl, Anna Mae
    [J]. HEPATOLOGY, 2009, 50 (06) : 2007 - 2013
  • [7] TGF-β enhances alcohol dependent hepatocyte damage via down-regulation of alcohol dehydrogenase I
    Ciuclan, Loredana
    Ehnert, Sabrina
    Ilkavets, Iryna
    Weng, Hong-Lei
    Gaitantzi, Haristi
    Tsukamoto, Hidekazu
    Ueberham, Elke
    Meindl-Beinker, Nadja M.
    Singer, Manfred V.
    Breitkopf, Katja
    Dooley, Steven
    [J]. JOURNAL OF HEPATOLOGY, 2010, 52 (03) : 407 - 416
  • [8] Role of cytokines in the pathogenesis of non-alcoholic fatty liver disease
    Das S.K.
    Balakrishnan V.
    [J]. Indian Journal of Clinical Biochemistry, 2011, 26 (2) : 202 - 209
  • [9] Denton CP, 2007, ARTHRITIS RHEUM-US, V56, P323, DOI 10.1002/art.22289
  • [10] Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II
    Dituri, Francesco
    Mazzocca, Antonio
    Juan Peidro, Fernando
    Papappicco, Patrizia
    Fabregat, Isabel
    De Santis, Flavia
    Paradiso, Angelo
    Sabba, Carlo
    Giannelli, Gianluigi
    [J]. PLOS ONE, 2013, 8 (06):
123456